Skip to main content

Advertisement

Table 2 A summary of the studies investigating a correlation between the extent of TIL infiltrate and responses to neoadjuvant/adjuvant chemotherapy in breast cancer

From: Relevance of tumor-infiltrating lymphocytes in breast cancer

Breast cancer subtype (Number of patients) TILs predictive of pCR? TILs predictive of disease-free or overall survival? Reference Chemotherapy used
All patients (56) Yes ND [60] Anthracycline/taxane or epirubicin, cyclophosphamide, and capecitabine
All patients (73) Yes ND [139] Anthracycline/taxane based
ER+/PR+ (659) Yes ND [59] Anthracycline/cyclophosphamide/taxane
ERPR (266) Yes ND
All patients (1334)   Yes (total or distant stromal CD8+) [75] Cyclophosphamide/methotrexate/fluorouracil
ER+ (911)   No (intratumoral or adjacent stroma CD8+)
ER (485)   No (total CD8+)
HER2+ (169)   Yes (total CD8+)
HER2 (1106)   No (total CD8+)
Yes (total CD8+)
ER (268) Yes Yes [38] Fluorouracil/epirubicin/cyclophosphamide or docetaxel and docetaxel plus epirubicin
One cohort of 113, one of 255
All patients (3403)   No [140] Adjuvant systemic therapy
ER (927)   Yes
ER+ (2456)   No
HER2+ (216)   No
TNBC (535)   Yes
All patients (180) Yes ND [37] Anthracycline/cyclophosphamide or cyclophosphamide/epirubicin/5-fluorouracil
TNBC (82) Yes ND
HER2+ERPR (42) No ND
HER2ER+/PR+ (46) No ND
All patients (845) Yes ND [61] Meta-analysis: anthracycline with or without taxane-based NAC
ERHER2 Yes ND
HER2+ (116) Yes ND
ER+Her2 Yes ND
All patients (68) Yes ND [141] Anthracycline and/or taxane-based treatment
All patients (180) Yes ND [71] Paclitaxel then fluorouracil/epirubicin/cyclophosphamide
HER2 (313) Yes ND [63] Anthracycline/taxane
All patients (2009) ND No [39] Doxorubicin followed by three cycles of cyclophosphamide/methotrexate/fluorouracil
ER/HER2 (1079) ND No
HER2+ (297) ND No
TNBC (256) ND Yes
All patients (153) Yes ND [72] Anthracycline and/or taxane-based treatment
TNBC (38) Yes
Non-TNBC (115) Yes (If CD8+ component analyzed), No if CD4+ analyzed
All patients (175) Yes ND [73] Anthracycline and/or taxane-based treatment or herceptin+NAC
All patients (12439) ND ND [142] Cyclophosphamide/methotrexate/fluorouracil or epirubicin plus fluorouracil
ER (3591) ND Yes
ER+ (8775) ND No
ER+HER2+ (772) ND Yes
All patients (934) ND No [65] Docetaxel or vinorelbine, followed by three cycles of fluorouracil/epirubicin/cyclophosphamide
ER+HER2 (591) ND No
HER2+ (209) ND No
TNBC (134) ND Yes
TNBC (278) Yes Yes [64] Anthracycline-based neoadjuvant or anthracycline/taxane
TNBC (47) Yes ND [143] Panitumumab plus anthracycline/taxane-based chemotherapy
TNBC (481) ND Yes [66] Doxorubicin plus cyclophosphamide and taxol/docetaxol
All patients (580) Yes ND [41] Anthracycline/taxane with or without carboplatin
TNBC (314) Yes ND
HER2+ (266) Yes
  1. ER estrogen receptor, HER2 human epidermal growth factor receptor 2, NAC neoadjuvant chemotherapy, ND not determined, PR progesterone receptor, TNBC triple negative breast cancer